{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T01:47:56Z","timestamp":1771033676672,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,4,24]],"date-time":"2019-04-24T00:00:00Z","timestamp":1556064000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin J Gastroenterol"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1007\/s12328-019-00983-x","type":"journal-article","created":{"date-parts":[[2019,4,24]],"date-time":"2019-04-24T17:02:35Z","timestamp":1556125355000},"page":"355-360","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Interstitial pneumonia suspected during regorafenib administration and exacerbated by subsequent therapy with lenvatinib for unresectable hepatocellular carcinoma"],"prefix":"10.1007","volume":"12","author":[{"given":"Kohei","family":"Kotani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaru","family":"Enomoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masako","family":"Okada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kanako","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Motoyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Hagihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sawako","family":"Uchida-Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyasu","family":"Morikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiki","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Tamori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norifumi","family":"Kawada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,4,24]]},"reference":[{"key":"983_CR1","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378\u201390.","journal-title":"N Engl J Med"},{"key":"983_CR2","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","volume":"10","author":"AL Cheng","year":"2009","unstructured":"Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25\u201334.","journal-title":"Lancet Oncol"},{"key":"983_CR3","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","volume":"389","author":"J Bruix","year":"2017","unstructured":"Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389:56\u201366.","journal-title":"Lancet"},{"key":"983_CR4","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391:1163\u201373.","journal-title":"Lancet"},{"key":"983_CR5","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","volume":"381","author":"A Grothey","year":"2013","unstructured":"Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381:303\u201312.","journal-title":"Lancet"},{"key":"983_CR6","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S0140-6736(12)61857-1","volume":"381","author":"GD Demetri","year":"2013","unstructured":"Demetri GD, Reichardt P, Kang YK, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381:295\u2013302.","journal-title":"Lancet"},{"key":"983_CR7","doi-asserted-by":"publisher","first-page":"543","DOI":"10.5009\/gnl.2010.4.4.543","volume":"4","author":"HJ Myung","year":"2010","unstructured":"Myung HJ, Jeong SH, Kim JW, et al. Sorafenib-induced interstitial pneumonitis in a patient with hepatocellular carcinoma: a case report. Gut Liver. 2010;4:543\u20136.","journal-title":"Gut Liver"},{"key":"983_CR8","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.lungcan.2009.10.007","volume":"67","author":"S Ide","year":"2010","unstructured":"Ide S, Soda H, Hakariya T, et al. Interstitial pneumonia probably associated with sorafenib treatment: an alert of an adverse event. Lung Cancer. 2010;67:248\u201350.","journal-title":"Lung Cancer"},{"key":"983_CR9","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s12328-012-0339-9","volume":"5","author":"H Takeda","year":"2012","unstructured":"Takeda H, Nishikawa H, Iguchi E, et al. Sorafenib-induced acute interstitial pneumonia in patients with advanced hepatocellular carcinoma: report of three cases. Clin J Gastroenterol. 2012;5:407\u201312.","journal-title":"Clin J Gastroenterol"},{"key":"983_CR10","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.3892\/ol.2015.2934","volume":"9","author":"T Yamaguchi","year":"2015","unstructured":"Yamaguchi T, Seki T, Miyasaka C, et al. Interstitial pneumonia induced by sorafenib in a patient with hepatocellular carcinoma: an autopsy case report. Oncol Lett. 2015;9:1633\u20136.","journal-title":"Oncol Lett"},{"key":"983_CR11","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1200\/JCO.2005.04.9866","volume":"24","author":"M Ando","year":"2006","unstructured":"Ando M, Okamoto I, Yamamoto N, et al. Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol. 2006;24:2549\u201356.","journal-title":"J Clin Oncol"},{"key":"983_CR12","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1111\/cas.12550","volume":"105","author":"A Gemma","year":"2014","unstructured":"Gemma A, Kudoh S, Ando M, et al. Final safety and efficacy of erlotinib in the phase 4 POLARSTAR surveillance study of 10 708 Japanese patients with non-small-cell lung cancer. Cancer Sci. 2014;105:1584\u201390.","journal-title":"Cancer Sci"},{"key":"983_CR13","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/1465-9921-13-39","volume":"13","author":"O Matsuno","year":"2012","unstructured":"Matsuno O. Drug-induced interstitial lung disease: mechanisms and best diagnostic approaches. Respir Res. 2012;13:39.","journal-title":"Respir Res"},{"key":"983_CR14","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1007\/s00280-011-1737-2","volume":"68","author":"JH Min","year":"2011","unstructured":"Min JH, Lee HY, Lim H, et al. Drug-induced interstitial lung disease in tyrosine kinase inhibitor therapy for non-small cell lung cancer: a review on current insight. Cancer Chemother Pharmacol. 2011;68:1099\u2013109.","journal-title":"Cancer Chemother Pharmacol"},{"key":"983_CR15","doi-asserted-by":"publisher","first-page":"136","DOI":"10.7326\/0003-4819-134-2-200101160-00015","volume":"134","author":"M Selman","year":"2001","unstructured":"Selman M, King TE, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med. 2001;134:136\u201351.","journal-title":"Ann Intern Med"},{"key":"983_CR16","doi-asserted-by":"publisher","first-page":"4893","DOI":"10.1038\/srep04893","volume":"4","author":"C Li","year":"2014","unstructured":"Li C, Wei R, Jones-Hall YL, et al. Epidermal growth factor receptor (EGFR) pathway genes and interstitial lung disease: an association study. Sci Rep. 2014;4:4893.","journal-title":"Sci Rep"},{"key":"983_CR17","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1164\/rccm.201002-0188OC","volume":"183","author":"C Harada","year":"2011","unstructured":"Harada C, Kawaguchi T, Ogata-Suetsugu S, et al. EGFR tyrosine kinase inhibition worsens acute lung injury in mice with repairing airway epithelium. Am J Respir Crit Care Med. 2011;183:743\u201351.","journal-title":"Am J Respir Crit Care Med"},{"key":"983_CR18","doi-asserted-by":"publisher","first-page":"550","DOI":"10.18632\/oncotarget.939","volume":"4","author":"Y Ishiguro","year":"2013","unstructured":"Ishiguro Y, Ishiguro H, Miyamoto H. Epidermal growth factor receptor tyrosine kinase inhibition up-regulates interleukin-6 in cancer cells and induces subsequent development of interstitial pneumonia. Oncotarget. 2013;4:550\u20139.","journal-title":"Oncotarget"},{"key":"983_CR19","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1183\/09031936.04.00065504","volume":"25","author":"Y Abadie","year":"2005","unstructured":"Abadie Y, Bregeon F, Papazian L, et al. Decreased VEGF concentration in lung tissue and vascular injury during ARDS. Eur Respir J. 2005;25:139\u201346.","journal-title":"Eur Respir J"},{"key":"983_CR20","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1365-3083.2008.02222.x","volume":"69","author":"M Vasakova","year":"2009","unstructured":"Vasakova M, Sterclova M, Kolesar L, et al. Bronchoalveolar lavage fluid cellular characteristics, functional parameters and cytokine and chemokine levels in interstitial lung diseases. Scand J Immunol. 2009;69:268\u201374.","journal-title":"Scand J Immunol"},{"key":"983_CR21","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1183\/09031936.00060708","volume":"33","author":"S McKeown","year":"2009","unstructured":"McKeown S, Richter AG, O\u2019Kane C, et al. MMP expression and abnormal lung permeability are important determinants of outcome in IPF. Eur Respir J. 2009;33:77\u201384.","journal-title":"Eur Respir J"},{"key":"983_CR22","doi-asserted-by":"publisher","first-page":"2164","DOI":"10.1097\/01.CCM.0000281451.73202.F6","volume":"35","author":"JR Roberts","year":"2007","unstructured":"Roberts JR, Perkins GD, Fujisawa T, et al. Vascular endothelial growth factor promotes physical wound repair and is anti-apoptotic in primary distal lung epithelial and A549 cells. Crit Care Med. 2007;35:2164\u201370.","journal-title":"Crit Care Med"},{"key":"983_CR23","doi-asserted-by":"publisher","first-page":"E1269","DOI":"10.3390\/ijms19051269","volume":"19","author":"SL Barratt","year":"2018","unstructured":"Barratt SL, Flower VA, Pauling JD, et al. VEGF (vascular endothelial growth factor) and fibrotic lung disease. Int J Mol Sci. 2018;19:E1269.","journal-title":"Int J Mol Sci"},{"key":"983_CR24","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1172\/JCI10259","volume":"106","author":"Y Kasahara","year":"2000","unstructured":"Kasahara Y, Tuder RM, Taraseviciene-Stewart L, et al. Inhibition of VEGF receptors causes lung cell apoptosis and emphysema. J Clin Investig. 2000;106:1311\u20139.","journal-title":"J Clin Investig"},{"key":"983_CR25","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1183\/09031936.00149614","volume":"45","author":"F Grimminger","year":"2015","unstructured":"Grimminger F, Gunther A, Vancheri C. The role of tyrosine kinases in the pathogenesis of idiopathic pulmonary fibrosis. Eur Respir J. 2015;45:1426\u201333.","journal-title":"Eur Respir J"},{"key":"983_CR26","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/S0076-6879(05)07047-3","volume":"407","author":"L Adnane","year":"2006","unstructured":"Adnane L, Trail PA, Taylor I, et al. Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF\/MEK\/ERK pathway in tumor cells and tyrosine kinases VEGFR\/PDGFR in tumor vasculature. Methods Enzymol. 2006;407:597\u2013612.","journal-title":"Methods Enzymol"},{"key":"983_CR27","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1002\/ijc.25864","volume":"129","author":"SM Wilhelm","year":"2011","unstructured":"Wilhelm SM, Dumas J, Adnane L, et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer. 2011;129:245\u201355.","journal-title":"Int J Cancer"},{"key":"983_CR28","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1406470","volume":"372","author":"M Schlumberger","year":"2015","unstructured":"Schlumberger M, Tahara M, Wirth LJ, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015;372:621\u201330.","journal-title":"N Engl J Med"},{"key":"983_CR29","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1159\/000486569","volume":"11","author":"R Kimura-Tsuchiya","year":"2018","unstructured":"Kimura-Tsuchiya R, Sasaki E, Nakamura I, et al. A case of squamous cell carcinoma of unknown primary that responded to the multi-tyrosine kinase inhibitor lenvatinib. Case Rep Oncol. 2018;11:75\u201380.","journal-title":"Case Rep Oncol"},{"key":"983_CR30","doi-asserted-by":"publisher","first-page":"638747","DOI":"10.1155\/2014\/638747","volume":"2014","author":"O Tohyama","year":"2014","unstructured":"Tohyama O, Matsui J, Kodama K, et al. Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models. J Thyroid Res. 2014;2014:638747.","journal-title":"J Thyroid Res"},{"key":"983_CR31","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s12032-010-9424-4","volume":"28","author":"LC Kuo","year":"2011","unstructured":"Kuo LC, Lin PC, Wang KF, et al. Successful treatment of gefitinib-induced acute interstitial pneumonitis with high-dose corticosteroid: a case report and literature review. Med Oncol. 2011;28:79\u201382.","journal-title":"Med Oncol"}],"container-title":["Clinical Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-019-00983-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12328-019-00983-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-019-00983-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,22]],"date-time":"2020-04-22T23:27:48Z","timestamp":1587598068000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12328-019-00983-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,24]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["983"],"URL":"https:\/\/doi.org\/10.1007\/s12328-019-00983-x","relation":{},"ISSN":["1865-7257","1865-7265"],"issn-type":[{"value":"1865-7257","type":"print"},{"value":"1865-7265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,24]]},"assertion":[{"value":"15 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures followed have been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human rights"}},{"value":"Informed consent was obtained from the patient for being included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}